NEWS HIGHLIGHTS
Published Studies Related to Denavir (Penciclovir)
Pharmacokinetics and safety of penciclovir following oral administration of famciclovir to cats. [2007.11]
OBJECTIVE: To investigate penciclovir pharmacokinetics following single and multiple oral administrations of famciclovir to cats.Famciclovir dosages of 15 mg/kg administered every 8 hours to cats are unlikely to result in plasma penciclovir concentrations with activity against feline herpesvirus-1.
Topical application of penciclovir cream for the treatment of herpes simplex facialis/labialis: a randomized, double-blind, multicentre, aciclovir-controlled trial. [2002.06]
BACKGROUND: Herpes simplex facialis/labialis (HSFL) is a common infectious skin disorder, caused mainly by herpes simplex virus (HSV) type 1, for which the topical application of a cream containing an antiviral agent for treatment of the disease has been widely utilized. OBJECTIVE: To explore the efficacy of the topical application of 1% penciclovir cream in the treatment of HSFL, and to compare its efficacy and safety with 3% aciclovir cream... CONCLUSION: Topical 1% penciclovir cream is as convenient and as effective as 3% aciclovir cream for the treatment of HSFL. Penciclovir cream may provide a good topical alternative to other types of therapy in the future.
Effective treatment of herpes simplex labialis with penciclovir cream: combined results of two trials. [2002.03]
BACKGROUND: Two randomized, double-blind, parallel-group clinical trials were conducted in Europe and North America to compare the efficacy and safety of topical 1 percent penciclovir cream with a placebo cream... CONCLUSIONS: The largest data set currently available on the treatment of recurrent HSL revealed that penciclovir cream significantly outperformed the placebo in healing classical lesions and resolution of pain. CLINICAL IMPLICATIONS: The authors found that penciclovir cream positively affects recurrent HSL, and dose frequency is vital to topical treatment. Even when penciclovir was applied late, it was effective in favorably altering the course of recurrent HSL.
A comparison of topical application of penciclovir 1% cream with acyclovir 3% cream for treatment of genital herpes: a randomized, double-blind, multicentre trial. [2000.09]
Genital herpes simplex virus (HSV) infection, a sexually transmitted disease (STD), is the commonest cause of ulcerative genital infections among the young and adult population. The significant association of genital ulceration and transmission of human immunodeficiency virus (HIV) has been shown in many studies...
Penciclovir cream for the treatment of sunlight-induced herpes simplex labialis: a randomized, double-blind, placebo-controlled trial. Penciclovir Cream Herpes Labialis Study Group. [2000.01]
OBJECTIVE: The purpose of this study was to further define the therapeutic value of penciclovir cream in the treatment of sunlight-induced herpes labialis by comparing its efficacy and tolerability with those of an inactive control (purified water)... CONCLUSIONS: Penciclovir cream has demonstrated efficacy for a broad range of clinically important outcomes. Significant effects on lesion area, lesion symptoms, and other lesion attributes extend the clinical efficacy of penciclovir cream beyond lesion healing.
Clinical Trials Related to Denavir (Penciclovir)
A Comparative Study of the Efficacy of Penciclovir 10mg/g (1%) Cream in Preventing the Appearance of Classical Lesion in Recurrent Cold Sore Sufferers [Completed]
Comparison of the efficacy of penciclovir 10 mg/g (1%) cream with that of vehicle at 72
hours in preventing the appearance of classical lesions following prodromal symptoms
(tingling or burning sensation) based on thermographic assessment among recurrent cold sore
sufferers.
Famciclovir Pediatric Formulation in Children 1 to 12 Years of Age With Herpes Simplex Infection [Completed]
This study will evaluate the safety and blood levels of a new pediatric formulation of
Famvir in children 1-12 years of age. In Part A, patients will receive a single dose of
famciclovir (12. 5 mg/kg) to assess pharmacokinetics (PK) and safety. In Part B, patients
will receive multiple doses of famciclovir alone or with concomitant oral anti-herpes
therapy to assess safety and tolerability. Part B will start only after PK data from Part A
had been analyzed.
Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis [Completed]
This study will assess the safety, tolerability of a single 1500 mg dose of famciclovir in
50 adolescents with recurrent herpes labialis. Eight of the 50 adolescents will also
participate in the pharmacokinetics (PK) assessment of famciclovir single 1500 mg dose
|
